Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. DBD
DBD logo

DBD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
72.480
1 Day change
-0.97%
52 Week Range
84.460
Analysis Updated At
2026/03/13
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Diebold Nixdorf Inc (DBD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and oversold technical indicators suggest a favorable entry point despite recent insider selling. The lack of recent news or congress trading data does not detract from the overall positive outlook.

Technical Analysis

The stock is currently oversold with an RSI of 19.992, indicating a potential rebound. The MACD histogram is negative and expanding, suggesting bearish momentum, but the converging moving averages hint at a potential reversal. The current price of $73.19 is near the S1 support level of $73.35, providing a solid entry point for long-term investors.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, with significantly higher call activity compared to puts.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • Strong Q4 2025 financial performance with revenue up 11.66% YoY, net income up 785.71% YoY, and EPS up 813.33% YoY.

  • Analysts have raised price targets to $100, reflecting confidence in the company's growth trajectory.

  • Hedge funds are actively buying, with a 200.38% increase in buying activity over the last quarter.

Neutral/Negative Catalysts

  • Insiders have increased selling activity by 113.75% over the last month.

  • Broader market weakness, with the S&P 500 down 1.52%, may weigh on short-term performance.

Financial Performance

Diebold Nixdorf reported exceptional Q4 2025 results. Revenue increased to $1.1042 billion, up 11.66% YoY. Net income surged to $49.6 million, up 785.71% YoY, and EPS increased to $1.37, up 813.33% YoY. Gross margin improved to 27.14%, up 13.51% YoY, showcasing strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts from Wedbush and DA Davidson have raised their price targets to $100 from $80, maintaining Outperform and Buy ratings, respectively. They cite strong order entry, backlog growth, and positive momentum from 2025 carrying into 2026 as key drivers of their optimism.

Wall Street analysts forecast DBD stock price to rise
2 Analyst Rating
Wall Street analysts forecast DBD stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 73.190
sliders
Low
80
Averages
80
High
80
Current: 73.190
sliders
Low
80
Averages
80
High
80
Wedbush
Outperform
maintain
$80 -> $100
AI Analysis
2026-02-13
Reason
Wedbush
Price Target
$80 -> $100
AI Analysis
2026-02-13
maintain
Outperform
Reason
Wedbush raised the firm's price target on Diebold to $100 from $80 and keeps an Outperform rating on the shares. While broader markets were under pressure, Diebold reported strong Q4 results and 2026 guidance, with full year EPS of $5.50 exceeding consensus estimate of $4.87, the firm notes. Wedbush come out of earnings incrementally more positive, and expects the momentum the company enjoyed in 2025 will carry through 2026 with this year in many ways mirroring last.
DA Davidson
Matt Summerville
Buy
maintain
$80 -> $100
2026-02-13
Reason
DA Davidson
Matt Summerville
Price Target
$80 -> $100
2026-02-13
maintain
Buy
Reason
DA Davidson analyst Matt Summerville raised the firm's price target on Diebold to $100 from $80 and keeps a Buy rating on the shares. The company continues to experience healthy order entry and backlog, inclusive of 9 logos added within its growing North America Retail platform, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DBD
Unlock Now

People Also Watch